Myriad Genetics, Inc. (NASDAQ:MYGN) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

MYGN has been the subject of a number of other research reports. Deutsche Bank AG increased their target price on shares of Myriad Genetics from $15.00 to $20.00 and gave the stock a “sell” rating in a research report on Monday, May 8th. J P Morgan Chase & Co reiterated an “underweight” rating and set a $16.00 target price on shares of Myriad Genetics in a research report on Friday, June 30th. Zacks Investment Research upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Monday, July 17th. Piper Jaffray Companies reiterated a “hold” rating and set a $22.00 target price on shares of Myriad Genetics in a research report on Friday, July 14th. Finally, Cowen and Company reiterated a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a research report on Friday, July 14th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $21.78.

Shares of Myriad Genetics (NASDAQ:MYGN) opened at 27.76 on Friday. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $28.39. The company’s 50 day moving average is $25.18 and its 200-day moving average is $20.92. The company has a market cap of $1.89 billion, a P/E ratio of 59.32 and a beta of 0.31.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.04. The company had revenue of $200.50 million during the quarter, compared to the consensus estimate of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the firm earned $0.36 EPS. Analysts expect that Myriad Genetics will post $1.05 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/08/12/myriad-genetics-inc-nasdaqmygn-lifted-to-buy-at-bidaskclub.html.

A number of large investors have recently bought and sold shares of the stock. Norges Bank bought a new stake in Myriad Genetics during the fourth quarter valued at $14,319,000. Arizona State Retirement System bought a new stake in Myriad Genetics during the first quarter valued at $682,000. Bank of New York Mellon Corp boosted its stake in Myriad Genetics by 131.2% in the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock valued at $17,632,000 after buying an additional 521,146 shares during the last quarter. Frontier Capital Management Co. LLC boosted its stake in Myriad Genetics by 1.4% in the first quarter. Frontier Capital Management Co. LLC now owns 3,075,954 shares of the company’s stock valued at $59,058,000 after buying an additional 41,432 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its stake in Myriad Genetics by 958.4% in the first quarter. Great West Life Assurance Co. Can now owns 97,514 shares of the company’s stock valued at $1,870,000 after buying an additional 88,301 shares during the last quarter.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.